Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

This study tests whether adding metformin (a diabetes drug being investigated for anti-cancer properties) to standard first-line chemotherapy improves outcomes for people with advanced soft tissue sarcoma, a cancer that forms in muscles, fat, or connective tissue. **You may be eligible if...** - You are 18 or older - You have advanced, unresectable or metastatic intermediate-to-high grade soft tissue sarcoma - You are about to start or have just started your first chemotherapy regimen for advanced/metastatic disease (within 4 weeks) - You are in good general health (ECOG 0–2) - Your kidney and liver function are adequate **You may NOT be eligible if...** - You have already received chemotherapy for advanced or metastatic disease (beyond the 4-week window) - You have kidney, liver, or other organ dysfunction that makes metformin unsafe Talk to your doctor to see if this trial is right for you.